Saturday, May 31, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

FDA’s Second Rejection Ends Intercept’s NASH Aspirations

Simon Osuji by Simon Osuji
June 23, 2023
in Technology
0
FDA’s Second Rejection Ends Intercept’s NASH Aspirations
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Pictured: FDA sign in front of building/Grandbrothers/iStock

Pictured: FDA sign in front of building/iStock, Grandbrothers

Thursday, the FDA denied Intercept Pharmaceuticals’ application for its obeticholic acid tablets, which the New Jersey biopharma was proposing to treat patients with pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis.

In its Complete Response Letter, the regulator said that Intercept’s New Drug Application for obeticholic acid (OCA) tablets “cannot be approved in its present form,” according to the company’s news release announcing the rejection.

For future submissions, Intercept would require—at the very least—the successful completion of the long-term outcomes part of its Phase III REGENERATE study, assessing OCA tablets in more than 2,400 patients.

The FDA’s verdict is in line with the Gastrointestinal Drugs Advisory Committee’s recommendations. In a meeting last month, the panel of external experts agreed that Intercept had not shown compelling evidence to establish a favorable risk-benefit profile for OCA.

This is the company’s second failed attempt to get OCA approved. The first NDA was filed in 2019, which the FDA accepted in November of the same year. In June 2020, however, the regulator turned down the application, indicating that Intercept’s data package, which relied on surrogate histopathologic endpoints to predict OCA’s efficacy, was not enough to establish that its benefits would outweigh its risks.

Following the initial rejection, Intercept launched REGENERATE, a randomized, double-blinded and placebo-controlled study. Two interim analyses from the study formed the foundation of Intercept’s resubmission, which it filed in December 2022 and which the FDA accepted in January 2023.

This second denial, however, appears to be final. Intercept also announced Thursday it will discontinue all investments and activities related to non-alcoholic steatohepatitis. The company will also kick off a restructuring initiative to reorient its operations and “strengthen its focus on rare and serious liver diseases,” according to the press release.

“We believe that taking decisive action to reshape Intercept will improve our long-term ability to grow our business, innovate for patients, and create value for shareholders,” Intercept CEO Jerry Durso said in a statement.

These realignment initiatives will also put Intercept on “an accelerated path to profitability beginning in 2024,” according to the company’s announcement.

OCA is a farnesoid X receptor agonist that helps prevent the toxic accumulation of bile acid in the liver. The FDA approved the drug in 2016 for the rare liver disease primary biliary cholangitis, for which OCA is marketed under the brand name Ocaliva. The oral drug carries a boxed label to warn against hepatic decompensation and failure.

Tristan Manalac is an independent science writer based in metro Manila, Philippines. He can be reached at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

 

Source link

Related posts

Moderna combination flu, COVID shot delayed amid FDA scrutiny

FDA clears Moderna’s new COVID vaccine, but with limits

May 31, 2025
Full Arvinas, Pfizer data confirm potential and limits of ‘Protac’ drug in breast cancer

Full Arvinas, Pfizer data confirm potential and limits of ‘Protac’ drug in breast cancer

May 31, 2025
Previous Post

Shaka iLembe: A Captivating Journey of History, Courage, and Legacy

Next Post

Minimalist master Tadao Ando on museum design, legacy and hope

Next Post
Minimalist master Tadao Ando on museum design, legacy and hope

Minimalist master Tadao Ando on museum design, legacy and hope

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

How Israel’s Invasion of Lebanon Might Cost Kamala Harris Michigan

How Israel’s Invasion of Lebanon Might Cost Kamala Harris Michigan

7 months ago
Nigerian tycoon Tony Elumelu’s UBA posts $189.6-million profit in H1 2024

Nigerian tycoon Tony Elumelu’s UBA posts $189.6-million profit in H1 2024

8 months ago
First-of-its-kind Survey On Menstrual Products Reveals Kenyan Women Face A Severe Lack Of Accessibility To Sanitary Pads And A Grave Risk Of Exploitation

First-of-its-kind Survey On Menstrual Products Reveals Kenyan Women Face A Severe Lack Of Accessibility To Sanitary Pads And A Grave Risk Of Exploitation

1 month ago
Working Dinner between State Minister for Foreign Affairs FUJII and H.E. Mr. Philemon YANG, President of the 79th session of the United Nations General Assembly (UNGA)

Working Dinner between State Minister for Foreign Affairs FUJII and H.E. Mr. Philemon YANG, President of the 79th session of the United Nations General Assembly (UNGA)

4 months ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • Matthew Slater, son of Jackson State great, happy to see HBCUs back at the forefront

    0 shares
    Share 0 Tweet 0
  • Dolly Varden Focuses on Adding Ounces the Remainder of 2023

    0 shares
    Share 0 Tweet 0
  • US Dollar Might Fall To 96-97 Range in March 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.